{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T13:42:31Z","timestamp":1767706951194,"version":"3.46.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T00:00:00Z","timestamp":1761350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T00:00:00Z","timestamp":1761350400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"The Key Project of the Scientific Research Development Fund of Kangda College, Nanjing Medical University","award":["KD2023KYJJ048"],"award-info":[{"award-number":["KD2023KYJJ048"]}]},{"name":"The Lianyungang Cancer Prevention and Treatment Science and Technology Development Program","award":["MS202309, ZD202306"],"award-info":[{"award-number":["MS202309, ZD202306"]}]},{"name":"The Key Project of the Natural Science Foundation of Bengbu Medical College","award":["2022byzd175, 2024byzd299"],"award-info":[{"award-number":["2022byzd175, 2024byzd299"]}]},{"name":"The Lianyungang Aging Health Research Project","award":["L202306, L202215"],"award-info":[{"award-number":["L202306, L202215"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-025-01879-6","type":"journal-article","created":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T05:08:40Z","timestamp":1761368920000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Plasma IL-6, IL-8 and IL-10 as predictors of response to PD-1 blockade immunochemotherapy in advanced gastric cancer"],"prefix":"10.1007","volume":"25","author":[{"given":"Fumeng","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juncun","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyue","family":"Tong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,25]]},"reference":[{"issue":"3","key":"1879_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"1879_CR2","doi-asserted-by":"publisher","first-page":"239","DOI":"10.2147\/CMAR.S149619","volume":"10","author":"R Sitarz","year":"2018","unstructured":"Sitarz R, Skierucha M, Mielko J, et al. Gastric cancer: epidemiology, prevention, classification, and treatment. Cancer Manag Res. 2018;10:239\u201348.","journal-title":"Cancer Manag Res"},{"issue":"1","key":"1879_CR3","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1186\/s12885-025-14206-9","volume":"25","author":"Y Ma","year":"2025","unstructured":"Ma Y, Li Y, Lin Z, et al. Safety and efficacy of systemic chemotherapy plus PD-1 inhibitor in combination with intravenous or intraperitoneal bevacizumab in gastric cancer with peritoneal metastasis. BMC Cancer. 2025;25(1):1010.","journal-title":"BMC Cancer"},{"issue":"5","key":"1879_CR4","doi-asserted-by":"publisher","first-page":"240","DOI":"10.3892\/ol.2025.14986","volume":"29","author":"YY Wu","year":"2025","unstructured":"Wu YY, Shao H. Research progress of sintilimab in the treatment of cancer (review). Oncol Lett. 2025;29(5):240.","journal-title":"Oncol Lett"},{"issue":"3","key":"1879_CR5","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","volume":"19","author":"JJ Havel","year":"2019","unstructured":"Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer. 2019;19(3):133\u201350.","journal-title":"Nat Rev Cancer"},{"issue":"7935","key":"1879_CR6","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41586-022-05388-4","volume":"611","author":"TW Wang","year":"2022","unstructured":"Wang TW, Johmura Y, Suzuki N, et al. Blocking PD-L1-PD-1 improves senescence surveillance and ageing phenotypes. Nature. 2022;611(7935):358\u201364.","journal-title":"Nature"},{"issue":"7903","key":"1879_CR7","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/s41586-022-04508-4","volume":"603","author":"K Shitara","year":"2022","unstructured":"Shitara K, Ajani JA, Moehler M, et al. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature. 2022;603(7903):942\u20138.","journal-title":"Nature"},{"issue":"1","key":"1879_CR8","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s13045-022-01362-9","volume":"15","author":"Q Wu","year":"2022","unstructured":"Wu Q, Qian W, Sun X, et al. Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. J Hematol Oncol. 2022;15(1):143.","journal-title":"J Hematol Oncol"},{"key":"1879_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1547850","volume":"12","author":"Z Komekbay","year":"2025","unstructured":"Komekbay Z, Shirazi R, Yessultanova G, et al. Bibliometric analysis of tumor marker application in gastric cancer diagnosis from 2019 to 2024. Front Med. 2025;12:1547850.","journal-title":"Front Med"},{"key":"1879_CR10","doi-asserted-by":"crossref","unstructured":"Fu L, Xie F, Sun P, et al. First clinical investigation to predict lymphovascular and\/or perineural invasion in gastric cancer using 18F-FAPI-42 PET\/CT parameters. Eur J Nucl Med Mol Imaging 2025.","DOI":"10.1007\/s00259-025-07325-9"},{"issue":"3","key":"1879_CR11","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.cell.2022.01.008","volume":"185","author":"G Morad","year":"2022","unstructured":"Morad G, Helmink BA, Sharma P, et al. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell. 2022;185(3):576.","journal-title":"Cell"},{"issue":"4","key":"1879_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0320193","volume":"20","author":"Y Zhao","year":"2025","unstructured":"Zhao Y, Han J, Yang R, et al. Evaluating the predictive significance of D-dimer in conjunction with CA724 for the postoperative outcomes in gastric cancer: a retrospective cohort analysis. PLoS ONE. 2025;20(4):e0320193.","journal-title":"PLoS ONE"},{"issue":"5","key":"1879_CR13","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v16.i5.107551","volume":"16","author":"L Ren","year":"2025","unstructured":"Ren L, Liu J, Xu YY, et al. Serum pro-inflammatory cytokines as potential biomarkers for the diagnosis of gastric carcinoma. World J Clin Oncol. 2025;16(5):107551.","journal-title":"World J Clin Oncol"},{"issue":"10","key":"1879_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2024.108564","volume":"50","author":"T Itami","year":"2024","unstructured":"Itami T, Kurokawa Y, Yoshioka R, et al. Measuring serum and drainage fluid interleukin-6 and tumor necrosis factor-\u03b1 levels for early detection of infectious complications after minimally invasive surgery for gastric cancer. Eur J Surg Oncol. 2024;50(10):108564.","journal-title":"Eur J Surg Oncol"},{"issue":"7","key":"1879_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26073236","volume":"26","author":"YY Wu","year":"2025","unstructured":"Wu YY, Chen MS, Chen IC, et al. Lidocaine modulates cytokine production and reprograms the tumor immune microenvironment to enhance anti-tumor immune responses in gastric cancer. Int J Mol Sci. 2025;26(7):3236.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"1879_CR16","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1002\/jcp.25822","volume":"233","author":"V Bagheri","year":"2018","unstructured":"Bagheri V, Memar B, Momtazi AA, et al. Cytokine networks and their association with Helicobacter pylori infection in gastric carcinoma. J Cell Physiol. 2018;233(4):2791\u2013803.","journal-title":"J Cell Physiol"},{"issue":"7","key":"1879_CR17","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a028571","volume":"10","author":"A Yoshimura","year":"2018","unstructured":"Yoshimura A, Ito M, Chikuma S, et al. Negative regulation of cytokine signaling in immunity. Cold Spring Harb Perspect Biol. 2018;10(7):a028571.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"6","key":"1879_CR18","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649\u201355.","journal-title":"Am J Clin Oncol"},{"issue":"13","key":"1879_CR19","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1200\/JCO.2015.64.0391","volume":"34","author":"FS Hodi","year":"2016","unstructured":"Hodi FS, Hwu WJ, Kefford R, et al. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J Clin Oncol. 2016;34(13):1510\u20137.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1879_CR20","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1080\/07357907.2023.2267675","volume":"41","author":"M Boutros","year":"2023","unstructured":"Boutros M, Attieh F, Chartouni A, et al. Beyond the horizon: a cutting-edge review of the latest checkpoint inhibitors in cancer treatment. Cancer Invest. 2023;41(9):757\u201373.","journal-title":"Cancer Invest"},{"issue":"10","key":"1879_CR21","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1097\/RLU.0000000000004281","volume":"47","author":"X Ji","year":"2022","unstructured":"Ji X, Dong A. FDG PET\/CT in prostate metastasis from gastric cancer. Clin Nucl Med. 2022;47(10):918\u201320.","journal-title":"Clin Nucl Med"},{"issue":"2","key":"1879_CR22","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"issue":"8","key":"1879_CR23","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1093\/annonc\/mdy218","volume":"29","author":"TR Cottrell","year":"2018","unstructured":"Cottrell TR, Thompson ED, Forde PM, et al. Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC). Ann Oncol. 2018;29(8):1853\u201360.","journal-title":"Ann Oncol"},{"issue":"7","key":"1879_CR24","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1093\/annonc\/mdx178","volume":"28","author":"E Sa\u00e2da-Bouzid","year":"2017","unstructured":"Sa\u00e2da-Bouzid E, Defaucheux C, Karabajakian A, et al. Hyperprogression during anti-PD-1\/PD-L1 therapy in patients with recurrent and\/or metastatic head and neck squamous cell carcinoma. Ann Oncol. 2017;28(7):1605\u201311.","journal-title":"Ann Oncol"},{"issue":"18","key":"1879_CR25","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1093\/jnci\/djq310","volume":"102","author":"A Hoos","year":"2010","unstructured":"Hoos A, Eggermont AM, Janetzki S, et al. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst. 2010;102(18):1388\u201397.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"1879_CR26","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/modpathol.2017.156","volume":"31","author":"JM Taube","year":"2018","unstructured":"Taube JM, Galon J, Sholl LM, et al. Implications of the tumor immune microenvironment for staging and therapeutics. Mod Pathol. 2018;31(2):214\u201334.","journal-title":"Mod Pathol"},{"issue":"3","key":"1879_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005841","volume":"11","author":"LL Liu","year":"2023","unstructured":"Liu LL, Skribek M, Harmenberg U, et al. Systemic inflammatory syndromes as life-threatening side effects of immune checkpoint inhibitors: case report and systematic review of the literature. J Immunother Cancer. 2023;11(3):e005841.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"1879_CR28","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s10238-025-01676-1","volume":"25","author":"F Yang","year":"2025","unstructured":"Yang F, Shaibu Z, Liu Q, et al. Cytokine profiles as predictive biomarkers for treatment outcomes in advanced gastric cancer patients undergoing PD-1 blockade immunochemotherapy: a meta-analysis. Clin Exp Med. 2025;25(1):136.","journal-title":"Clin Exp Med"},{"issue":"5","key":"1879_CR29","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/s41591-020-0856-x","volume":"26","author":"KA Schalper","year":"2020","unstructured":"Schalper KA, Carleton M, Zhou M, et al. Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors. Nat Med. 2020;26(5):688\u201392.","journal-title":"Nat Med"},{"issue":"17","key":"1879_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22179414","volume":"22","author":"HJ An","year":"2021","unstructured":"An HJ, Chon HJ, Kim C. Peripheral blood-based biomarkers for immune checkpoint inhibitors. Int J Mol Sci. 2021;22(17):9414.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1879_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000842","volume":"8","author":"AS Laino","year":"2020","unstructured":"Laino AS, Woods D, Vassallo M, et al. Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition. J Immunother Cancer. 2020;8(1):e000842.","journal-title":"J Immunother Cancer"},{"key":"1879_CR32","doi-asserted-by":"publisher","first-page":"3604935","DOI":"10.1155\/2024\/3604935","volume":"2024","author":"J Liu","year":"2024","unstructured":"Liu J, Mao Y, Mao C, et al. An on-treatment decreased trend of serum IL-6 and IL-8 as predictive markers quickly reflects short-term efficacy of PD-1 blockade immunochemotherapy in patients with advanced gastric cancer. J Immunol Res. 2024;2024:3604935.","journal-title":"J Immunol Res"},{"key":"1879_CR33","doi-asserted-by":"publisher","first-page":"1553882","DOI":"10.3389\/fimmu.2025.1553882","volume":"16","author":"H Ma","year":"2025","unstructured":"Ma H, Zhang S, Jiao P, et al. Serum IL-6 predicts immunotherapy-related adverse and outcome in advanced gastric and esophageal cancer patients with anti-PD-1 treatment. Front Immunol. 2025;16:1553882.","journal-title":"Front Immunol"},{"issue":"6","key":"1879_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26062534","volume":"26","author":"F Lospinoso Severini","year":"2025","unstructured":"Lospinoso Severini F, Falco G, Notarangelo T. Role of soluble cytokine receptors in gastric cancer development and chemoresistance. Int J Mol Sci. 2025;26(6):2534.","journal-title":"Int J Mol Sci"},{"key":"1879_CR35","doi-asserted-by":"publisher","first-page":"1559508","DOI":"10.3389\/fimmu.2025.1559508","volume":"16","author":"Z He","year":"2025","unstructured":"He Z, Dang J, Cui X, et al. The distinct role of IL-34 and IL-35 in gastric cancer. Front Immunol. 2025;16:1559508.","journal-title":"Front Immunol"},{"key":"1879_CR36","doi-asserted-by":"publisher","first-page":"1002312","DOI":"10.37349\/etat.2025.1002312","volume":"6","author":"MMC Marimuthu","year":"2025","unstructured":"Marimuthu MMC, Balamurugan BS, Sundaram VA, et al. Cytokine-based immunotherapy for gastric cancer: targeting inflammation for tumor control. Explor Target Antitumor Ther. 2025;6:1002312.","journal-title":"Explor Target Antitumor Ther"},{"key":"1879_CR37","doi-asserted-by":"publisher","first-page":"1430301","DOI":"10.3389\/fimmu.2024.1430301","volume":"15","author":"H Liu","year":"2024","unstructured":"Liu H, Zhou C, Jiang H, et al. Prognostic role of serum cytokines level in non-small cell lung cancer patients with anti-PD-1 and chemotherapy combined treatment. Front Immunol. 2024;15:1430301.","journal-title":"Front Immunol"},{"issue":"11","key":"1879_CR38","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1080\/14728222.2021.2011859","volume":"25","author":"N Silvestris","year":"2021","unstructured":"Silvestris N, Argentiero A, Brunetti O, et al. PD-L1 and Notch as novel biomarkers in pancreatic sarcomatoid carcinoma: a pilot study. Expert Opin Ther Targets. 2021;25(11):1007\u201316.","journal-title":"Expert Opin Ther Targets"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01879-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01879-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01879-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:51:33Z","timestamp":1764917493000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01879-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,25]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1879"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01879-6","relation":{},"ISSN":["1591-9528"],"issn-type":[{"type":"electronic","value":"1591-9528"}],"subject":[],"published":{"date-parts":[[2025,10,25]]},"assertion":[{"value":"27 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there are no financial or personal conflicts of interest that could have influenced the work presented in this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol complies with the ethical standards outlined in the 1975 Declaration of Helsinki. Prior approval was obtained from the Ethics Committee of the Second People\u2019s Hospital of Lianyungang (Approval No. 2024K013).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"331"}}